HRK and cancer: Of note, epigenetic suppression of HRK has been implicated in the pathogenesis of several human cancers including high-grade lymphomas [34, 35], and NOXA has been identified as a rheostat for venetoclax sensitivity in different types of blood malignancies [36–38].